Exact Sciences closed 2025 with $3.25 billion in total revenue, marking an 18% year-over-year increase—fueled largely by its cancer screening portfolio, including stool-based colorectal cancer screening test Cologuard.
Screening revenue reached $2.53 billion, reflecting continued uptake of non-invasive, at-home CRC testing among average-risk adults aged 45 and older. Since launch, Cologuard has been used more than 20 million times, highlighting growing patient and provider preference for guideline-supported alternatives to colonoscopy.
The company is now expanding beyond stool-based diagnostics, having secured exclusive U.S. rights to Freenome’s blood-based colorectal cancer screening test—signaling a strategic move into multi-modal CRC detection. Meanwhile, next-generation platforms such as Cancerguard (multi-cancer early detection) and Oncodetect (molecular residual disease monitoring) aim to broaden Exact Sciences’ footprint across the cancer care continuum.
Pending regulatory approvals, the company’s proposed acquisition by Abbott—expected in Q2 2026—could further accelerate its global push into earlier, less invasive cancer detection.